Cargando…

Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients

Urothelial bladder cancer (BCa) is the ninth most commonly diagnosed cancer worldwide and accounts for approximately 3% of global cancer diagnoses. We are interested in prognostic markers that may characterize tumor cells (TCs) and immune cells (ICs) and their relationship in BCa. A potential candid...

Descripción completa

Detalles Bibliográficos
Autores principales: Eckstein, Markus, Lieb, Verena, Jung, Rudolf, Sikic, Danijel, Weigelt, Katrin, Stöhr, Robert, Geppert, Carol, Weyerer, Veronika, Bertz, Simone, Serrero, Ginette, Yue, Binbin, Hartmann, Arndt, Wullich, Bernd, Taubert, Helge, Wach, Sven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306318/
https://www.ncbi.nlm.nih.gov/pubmed/34359965
http://dx.doi.org/10.3390/cells10071796
_version_ 1783727780075143168
author Eckstein, Markus
Lieb, Verena
Jung, Rudolf
Sikic, Danijel
Weigelt, Katrin
Stöhr, Robert
Geppert, Carol
Weyerer, Veronika
Bertz, Simone
Serrero, Ginette
Yue, Binbin
Hartmann, Arndt
Wullich, Bernd
Taubert, Helge
Wach, Sven
author_facet Eckstein, Markus
Lieb, Verena
Jung, Rudolf
Sikic, Danijel
Weigelt, Katrin
Stöhr, Robert
Geppert, Carol
Weyerer, Veronika
Bertz, Simone
Serrero, Ginette
Yue, Binbin
Hartmann, Arndt
Wullich, Bernd
Taubert, Helge
Wach, Sven
author_sort Eckstein, Markus
collection PubMed
description Urothelial bladder cancer (BCa) is the ninth most commonly diagnosed cancer worldwide and accounts for approximately 3% of global cancer diagnoses. We are interested in prognostic markers that may characterize tumor cells (TCs) and immune cells (ICs) and their relationship in BCa. A potential candidate marker that meets these criteria is progranulin (GP88), which is expressed separately in TCs and ICs. We analyzed GP88 expression by immunohistochemistry (IHC) in 196 muscle-invasive BCa samples using a tissue microarray. The immunoreactive score for GP88 staining in TCs and the percentage of GP88-positive ICs was determined. An easy cutoff for the staining status of TCs (positive vs. negative) and ICs (0% vs. >0%) and, more generally, negative vs. positive GP88 staining could be applied. We detected 93 patients (47.4%) and 92 patients (46.9%) with GP88-positive TCs or ICs, respectively. The IHC results were correlated with clinicopathological and survival data. Positive GP88 staining in TCs appeared to be an independent poor prognostic factor for disease-specific survival (DSS) (RR (relative risk) = 1.74; p = 0.009) and recurrence-free survival (RFS) (RR = 1.92; p = 0.002). In contrast, negative GP88 staining in ICs was an independent negative predictor for overall survival (OS) (RR = 2.18; p < 0.001), DSS (RR = 2.84; p < 0.001) and RFS (RR = 2.91; p < 0.001) in multivariate Cox’s regression analysis. When combining GP88 staining in TCs and ICs, a specific combination of GP88-positive TCs and GP88-negative ICs was associated with a 2.54-fold increased risk of death, a 4.21-fold increased risk of disease-specific death and a 4.81-fold increased risk of recurrence compared to GP88-negative TCs and GP88-positive ICs. In summary, GP88 positivity in TCs is a negative prognostic factor for DSS and RFS. In addition, GP88 positivity can mark ICs that are associated with a good prognosis (OS, DSS and RFS). The combination of GP88 staining in TCs and ICs appears to be a significant independent prognostic biomarker in muscle-invasive BCa.
format Online
Article
Text
id pubmed-8306318
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83063182021-07-25 Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients Eckstein, Markus Lieb, Verena Jung, Rudolf Sikic, Danijel Weigelt, Katrin Stöhr, Robert Geppert, Carol Weyerer, Veronika Bertz, Simone Serrero, Ginette Yue, Binbin Hartmann, Arndt Wullich, Bernd Taubert, Helge Wach, Sven Cells Article Urothelial bladder cancer (BCa) is the ninth most commonly diagnosed cancer worldwide and accounts for approximately 3% of global cancer diagnoses. We are interested in prognostic markers that may characterize tumor cells (TCs) and immune cells (ICs) and their relationship in BCa. A potential candidate marker that meets these criteria is progranulin (GP88), which is expressed separately in TCs and ICs. We analyzed GP88 expression by immunohistochemistry (IHC) in 196 muscle-invasive BCa samples using a tissue microarray. The immunoreactive score for GP88 staining in TCs and the percentage of GP88-positive ICs was determined. An easy cutoff for the staining status of TCs (positive vs. negative) and ICs (0% vs. >0%) and, more generally, negative vs. positive GP88 staining could be applied. We detected 93 patients (47.4%) and 92 patients (46.9%) with GP88-positive TCs or ICs, respectively. The IHC results were correlated with clinicopathological and survival data. Positive GP88 staining in TCs appeared to be an independent poor prognostic factor for disease-specific survival (DSS) (RR (relative risk) = 1.74; p = 0.009) and recurrence-free survival (RFS) (RR = 1.92; p = 0.002). In contrast, negative GP88 staining in ICs was an independent negative predictor for overall survival (OS) (RR = 2.18; p < 0.001), DSS (RR = 2.84; p < 0.001) and RFS (RR = 2.91; p < 0.001) in multivariate Cox’s regression analysis. When combining GP88 staining in TCs and ICs, a specific combination of GP88-positive TCs and GP88-negative ICs was associated with a 2.54-fold increased risk of death, a 4.21-fold increased risk of disease-specific death and a 4.81-fold increased risk of recurrence compared to GP88-negative TCs and GP88-positive ICs. In summary, GP88 positivity in TCs is a negative prognostic factor for DSS and RFS. In addition, GP88 positivity can mark ICs that are associated with a good prognosis (OS, DSS and RFS). The combination of GP88 staining in TCs and ICs appears to be a significant independent prognostic biomarker in muscle-invasive BCa. MDPI 2021-07-15 /pmc/articles/PMC8306318/ /pubmed/34359965 http://dx.doi.org/10.3390/cells10071796 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Eckstein, Markus
Lieb, Verena
Jung, Rudolf
Sikic, Danijel
Weigelt, Katrin
Stöhr, Robert
Geppert, Carol
Weyerer, Veronika
Bertz, Simone
Serrero, Ginette
Yue, Binbin
Hartmann, Arndt
Wullich, Bernd
Taubert, Helge
Wach, Sven
Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients
title Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients
title_full Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients
title_fullStr Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients
title_full_unstemmed Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients
title_short Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients
title_sort combination of gp88 expression in tumor cells and tumor-infiltrating immune cells is an independent prognostic factor for bladder cancer patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306318/
https://www.ncbi.nlm.nih.gov/pubmed/34359965
http://dx.doi.org/10.3390/cells10071796
work_keys_str_mv AT ecksteinmarkus combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients
AT liebverena combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients
AT jungrudolf combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients
AT sikicdanijel combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients
AT weigeltkatrin combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients
AT stohrrobert combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients
AT geppertcarol combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients
AT weyererveronika combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients
AT bertzsimone combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients
AT serreroginette combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients
AT yuebinbin combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients
AT hartmannarndt combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients
AT wullichbernd combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients
AT tauberthelge combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients
AT wachsven combinationofgp88expressionintumorcellsandtumorinfiltratingimmunecellsisanindependentprognosticfactorforbladdercancerpatients